Seres Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.34 | -$0.34 | -$0.34 |
| Q2 2024 | 1 | -$0.27 | -$0.27 | -$0.27 |
| Q3 2024 | 4 | -$0.08 | -$0.07 | -$0.08 |
| Q4 2024 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q1 2025 | 2 | -$0.19 | -$0.19 | -$0.19 |
| Q2 2025 | 2 | -$0.18 | -$0.18 | -$0.18 |
| Q3 2025 | 2 | -$0.16 | -$0.16 | -$0.16 |
| Q4 2025 | 2 | -$0.16 | -$0.16 | -$0.16 |
Seres Therapeutics, Inc. Earnings Date And Information
Seres Therapeutics, Inc. last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.28 by $0.06. The company had revenue of 0 for the quarter and had revenue of 126.33 M for the year. Seres Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.89 diluted earnings per share) and currently has a price-to-earnings ratio of -0.76. Seres Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Seres Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2024 | Q2 2024 | -$0.28 | -$0.22 | 0.06 | $-263,833 | $0 |
| 05/08/2024 | Q1 2024 | -$0.36 | -$0.27 | 0.09 | $0 | |
| 03/05/2024 | Q4 2023 | -$0.40 | -$0.32 | 0.08 | $64,000 | |
| 11/02/2023 | Q3 2023 | -$0.47 | -$0.37 | 0.1 | $1.50 M | $310,000 |
| 08/08/2023 | Q2 2023 | $0.53 | $0.36 | -0.17 | $125.67 M | $126.47 M |
| 05/09/2023 | Q1 2023 | -$0.57 | -$0.57 | 0 | $-522,000 | |
| 03/07/2023 | Q4 2022 | -$0.41 | -$0.55 | -0.14 | $975,000 | |
| 11/02/2022 | Q3 2022 | -$0.45 | -$0.49 | -0.04 | $7.00 M | $3.44 M |
| 08/03/2022 | Q2 2022 | -$0.58 | -$0.70 | -0.12 | $4.54 M | $1.22 M |
| 05/04/2022 | Q1 2022 | -$0.56 | -$0.62 | -0.06 | $1.49 M | |
| 03/01/2022 | Q4 2021 | -$0.45 | -$0.54 | -0.09 | $7.22 M | |
| 11/10/2021 | Q3 2021 | -$0.46 | $0.74 | 1.2 | $28.52 M | $126.73 M |
| 08/03/2021 | Q2 2021 | -$0.41 | -$0.53 | -0.12 | $5.86 M | $5.26 M |
| 05/04/2021 | Q1 2021 | -$0.33 | -$0.39 | -0.06 | $5.72 M | |
| 03/02/2021 | Q4 2020 | -$0.26 | -$0.22 | 0.04 | $17.56 M | |
| 11/09/2020 | Q3 2020 | -$0.24 | -$0.36 | -0.12 | $7.27 M | $1.42 M |
| 07/28/2020 | Q2 2020 | -$0.26 | -$0.28 | -0.02 | $9.54 M | $6.05 M |
| 05/07/2020 | Q1 2020 | -$0.29 | -$0.28 | 0.01 | $8.19 M | |
| 03/02/2020 | Q4 2019 | -$0.26 | -$0.27 | -0.01 | $7.62 M | |
| 11/05/2019 | Q3 2019 | -$0.26 | -$0.23 | 0.03 | $6.70 M | $7.03 M |
Seres Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Seres Therapeutics, Inc.'s earnings date?
Seres Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did Seres Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Seres Therapeutics, Inc. (:MCRB) reported $-0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.28 by $0.06.
-
How can I listen to Seres Therapeutics, Inc.'s earnings conference call?
The conference call for Seres Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Seres Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Seres Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Seres Therapeutics, Inc. generate each year?
Seres Therapeutics, Inc. (:MCRB) has a recorded annual revenue of $126.33 M.
-
How much profit does Seres Therapeutics, Inc. generate each year?
Seres Therapeutics, Inc. (:MCRB) has a recorded net income of $126.33 M. Seres Therapeutics, Inc. has generated $-0.89 earnings per share over the last four quarters.
-
What is Seres Therapeutics, Inc.'s price-to-earnings ratio?
Seres Therapeutics, Inc. (:MCRB) has a price-to-earnings ratio of -0.76 and price/earnings-to-growth ratio is 0.01.
